Pacific released a research report on April 17 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) rapid revenue growth in 2023Q4 and domestic and foreign two-wheel drive sales growth; 2) 2023Q4 profitability improvement, reflecting the advantages of cost reduction and efficiency; 3) 2023 high dividend returns to shareholders, and high dividend rates highlight value; 4) continuous innovation in technology research and development, and channel changes drive performance growth. (Mainichi Keizai Shimbun)
太平洋4月17日发布研报称，给予荣泰健康（603579.SH）买入评级。评级理由主要包括：1）2023Q4营收快速增长，国内外双轮驱动销售增长；2）2023Q4盈利能力提升，降本增效优势体现；3）2023年高比例分红回报股东，高股息率凸显价值；4）技术研发持续创新，渠道变革推动业绩增长。（每日经济新闻）
Pacific released a research report on April 17 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) rapid revenue growth in 2023Q4 and domestic and foreign two-wheel drive sales growth; 2) 2023Q4 p
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.